# Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C

> **NCT02640547** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 394 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02640547
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-26
- **Primary completion:** 2017-03-29
- **Final completion:** 2017-03-29
- **Target enrollment:** 394 (ACTUAL)
- **Last updated:** 2018-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02640547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02640547, "Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02640547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*